Treatment with CuII(atsm) mitigated all of these ALS-like features [84], providing the first indication from an ALS-like in vivo model which does not involve mutant SOD1 for the protective activity of the treatment. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.